Title: Setting a course for preventing hepatitis E in low and lower-middle-income countries: A systematic review of burden and risk factors

Aybüke Koyuncu¹, Daniel Mapemba², Iza Ciglenecki³, Emily S. Gurley⁴, Andrew S. Azman^{3,4}

¹Independent Researcher, Atlanta, Georgia

²South African Field Epidemiology Training Program, National Institute for Communicable Diseases, Division of National Health Laboratory Services, Johannesburg, South Africa

³Médecins Sans Frontières, Geneva, Switzerland

⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Corresponding author:

Aybüke Koyuncu

699 Ponce de Leon

Atlanta, GA 30308

Phone: 858-204-3470, Email: akoyuncu@berkeley.edu

Abstract

Background

Hepatitis E virus is responsible for outbreaks of acute jaundice in Africa and Asia, many of which occur among displaced people or in crisis settings. While an efficacious vaccine for HEV has been developed, we lack key epidemiologic data needed to understand how best to use the vaccine for hepatitis E control in endemic countries.

Methods

We conducted a systematic review of articles published on hepatitis E in low and lower-middle-income countries (LMIC) in Africa and Asia. We searched PubMed, Scopus, and Embase databases to identify articles with data on anti-HEV IgG seroprevalence, outbreaks of HEV, or risk factors for HEV infection, disease, or death, and all relevant data were extracted. Using these data we describe the evidence around temporal and geographical distribution of HEV transmission and burden. We estimated pooled age-specific seroprevalence and assessed the consistency in risk factor estimates.

Results

We extracted data from 148 studies. Studies assessing anti-HEV IgG antibodies used 18 different commercial assays. Most cases of hepatitis E during outbreaks were not confirmed. Risk factor data suggested an increased likelihood of current or recent HEV infection and disease associated with fecal-oral transmission of HEV, as well as exposures to blood and animals.

Conclusion

Heterogeneity in diagnostic assays used and exposure and outcome assessment methods hinder public health efforts to quantify burden of disease and evaluate interventions over time and space. Prevention tools such as vaccines are available, but require a unified global strategy for hepatitis E control to justify widespread use.

Key words: hepatitis E, hepatitis E virus (HEV), seroprevalence, outbreaks, risk factors

Introduction

Hepatitis E virus (HEV) is a single-stranded RNA virus which causes over 3 million cases of symptomatic hepatitis each year (1). The global burden of HEV is predominantly attributable to genotypes 1 and 2, which are associated with sporadically occurring cases as well as large protracted outbreaks in low and middle income countries where access to clean water and sanitation is limited (1,2). HEV outbreaks disproportionately affect pregnant women, for whom the mortality rate due to hepatitis E has been reported to be as high as 25% (3).

While outbreaks of HEV genotypes 1 and 2 in low and lower-middle-income countries (LMIC) are caused by fecal contamination of drinking water, transmission of other HEV genotypes, predominantly 3 and 4, can cause acute sporadic cases of hepatitis.

Genotypes 3 and 4 are non-epidemic, are known to circulate in animal reservoirs, and can be spread through zoonotic transmission, consumption of raw or undercooked meat, blood transfusions, and organ donation (2–4). Although acute sporadic cases of HEV in high-income countries are typically associated with genotypes 3 and 4, the burden of these genotypes in LMIC remains unclear (2).

Access to clean water and sanitation could significantly reduce the transmission of HEV in LMIC, but household-level water and sanitation interventions often require behavioral change and have had mixed results in outbreak control (5). Outbreaks of HEV, many of which occur among displaced people or in crisis settings, are notoriously difficult to control in part due to the high proportion of asymptomatic and mildly symptomatic infections and limited options for clinical management of severe cases (3). One potential intervention strategy to control HEV transmission is a recombinant vaccine, HEV239 (Hecolin®; Inovax, Xiamen, China), which has been shown to be safe and highly efficacious in preventing HEV infection due to genotype 4, with pan-genotype protection expected (6). The World Health Organization (WHO) has not recommended the routine use of the vaccine in HEV endemic countries, citing a critical lack of epidemiologic data on the incidence of disease in the general population and in special subpopulations (7). In the absence of these data Hecolin is currently only recommended by WHO for consideration during HEV outbreaks, although at the time of writing this it has not been used in any outbreaks (7).

Burden-of-disease data, combined with information on key risk factors for HEV infection and disease can spur the use of existing prevention tools that may be capable of substantially reducing morbidity and mortality due to HEV in LMIC. A lack of data on the burden and transmission patterns of HEV precludes investments into a global strategy for control for hepatitis E (8). Given the clear pathway for WHO prequalification of the existing vaccine (9), a better understanding of the epidemiology of hepatitis E viruses is needed to set the agenda for global strategy and identify best practices to measure impact. Here we aim to review data on the epidemiology of hepatitis E in low and lower-

middle-income countries in Africa and Asia through systematic reviews of three domains of evidence, first through a review of seroprevalence studies, second a review of reported outbreak size and geography, and finally a review of risk factors for infection, disease and death.

Methods

Search Strategy

We searched PubMed, Scopus, and Embase to identify all studies with ‘hepatitis E’ in the article title that were published prior to November 2018, regardless of language. We uploaded search results to covidence (www.covidence.org), which we used to manage the subsequent steps of the review.

Study Selection

For both stages of study selection (abstract review, full text review) two independent reviewers screened each document for eligibility. All discrepancies between reviewers were reviewed by a third reviewer, who discussed with the original reviewers and decided upon the correct classification.

Studies were included if they satisfied the following inclusion criteria: (i) study in a low-income or lower-middle-income country in Africa or Asia according to 2019 World Bank country classifications (10); and (ii) includes serosurvey data (anti-HEV IgG only, IgG and/or IgM) in populations without known liver disease; or (iii) includes an outbreak description of HEV genotype 1, 2, or unidentified genotype; or (iv) includes effect size estimates (e.g. odds ratio, risk ratio) for potential risk factors for current or recent infection (anti-HEV IgM or RNA), disease, or death.

Studies were excluded if they met any of the following criteria: (i) abstract or full-text not available; (ii) abstract or full-text not in French, English or Spanish; (iii) non-human study of HEV; (iv) diagnostic, viral genetics, or immunologic study; (v) case series with no controls for any outcome; (vi) commentary, perspective, or review article; (vii) studies with duplicate data.

Data Extraction

A data extraction form developed by the authors was used to extract data from the full-text of all included studies. A plot digitizer (<https://apps.automeris.io/wpd/>) was used if data were only presented graphically. To gauge the consistency of the data extraction and to identify common errors, 10% of all studies in the data abstraction phase were extracted independently by two reviewers, and any discrepancies in data extracted were resolved by discussion and consensus. We used lessons from discrepancies in extracted data to adjust previous extractions and to ensure that future extractions did not have those errors.

Seroprevalence Studies

For studies reporting seroprevalence data, we extracted population type, lower and upper bounds for population age, diagnostic assay, test isotype (anti-HEV IgG or IgG+IgM), and the total number of samples tested and number of positive/negative samples. Within each study, data were extracted separately for each age stratum and unique population type: general population, blood donors, patients attending a hospital or clinic for non-liver related, non-pregnancy related issues, pregnant women, occupational groups exposed to animals (e.g. butchers, pig farmers), outbreak residents (i.e. individuals

identified in areas with an ongoing HEV outbreak) or other. Refugee and internally displaced populations that were not experiencing outbreaks were categorized as “other”. If studies reported seroprevalence data from the same population using different assays including Wantai assays (Wantai BioPharm, Beijing, China; considered the most reliable commercially available assay at the time of writing), we only extracted seroprevalence data based on Wantai assays (11).

Outbreak Descriptions

For studies describing outbreaks, we extracted the date of the first and last cases reported in the outbreak, whether the outbreak occurred in a refugee or displaced persons camp, HEV genotype(s) identified, suspected/confirmed case definitions and laboratory confirmation methods, number of suspected cases with confirmatory testing, average age (mean or median) of cases, number of suspected/confirmed cases, and number of suspected/confirmed deaths. Data on the number of suspected/confirmed cases and deaths were extracted within stratum of where cases were identified, namely: at health facilities, in communities, in institutions (e.g. prisons, army barracks), and not reported. The number of suspected/confirmed cases and deaths was extracted for the general population and also separately for pregnant/postpartum women and children under the age of 5. If multiple studies described the same outbreak (overlapping outbreak dates in the same geographic area and population) the most comprehensive outbreak report was extracted. Studies describing the same outbreak were combined only if they presented unique data (e.g. data on different subpopulations, number of deaths, etc.).

Risk Factors

For studies including risk factors for infection, disease, or death, we extracted outcome definition and confirmation method, estimator of association (e.g. odds ratio, risk ratio), effect size, 95% confidence interval, reference category for the estimator, and whether the estimator was adjusted for any covariates using regression analysis or matching. If both odds ratios and risk ratios were presented for the same risk factor, we extracted odds ratios. If risk factor data were reported for different case definitions of infection/disease within the same study, we extracted the most conservative case definition. We categorized each risk factor into one of the following groups: water, sanitation, hygiene, food and drink (non-water), exposure to blood or blood products, exposure to animals, age, sex, or other. Current and recent HEV infection and disease was defined in three categories: serologic evidence of anti-HEV IgM or RNA with no accompanying symptoms (“confirmed infection”), symptoms consistent with hepatitis (e.g. jaundice, elevated liver enzymes) without any serologic testing (“suspected disease”), or symptoms consistent with hepatitis with confirmation by IgM or HEV RNA (“confirmed disease”).

Data Analysis

We examined trends in the number of seroprevalence studies conducted over time, as well as variability in seroprevalence by age, population type, and diagnostic assay. Age-specific seroprevalence was calculated using the median age of tested individuals for each seroprevalence estimate. Seroprevalence estimates with no data on population age were excluded from analysis of seroprevalence by age.

We estimated outbreak duration using the difference between the date of the first and last cases reported in each outbreak description. The case fatality risk (CFR) was calculated separately among suspected cases and confirmed cases, and was defined as the number of suspected/confirmed deaths divided by the number of suspected/confirmed cases.

We categorized risk factors based on the general consensus of the literature on factors that increase HEV infection/disease/death risk and those that are protective. Risk factors lacking a hypothesized direction of effect (e.g. ethnicity) or with an unspecified reference group were excluded from further analysis. Household water sources and type of sanitation facilities were categorized as improved or unimproved according to 2019 World Health Organization/United Nations Children's Fund standard categories (12). A summary of risk factors and their corresponding exposures hypothesized to increase the likelihood of HEV infection/disease/death is provided in the Appendix (Supplemental Table 1). If studies reported unadjusted and adjusted estimates we included the adjusted estimates. We examined the proportion of risk factors that followed the hypothesized direction of effect (e.g. effect estimate >1 for risk factors hypothesized to increase risk) and the proportion that were statistically significant based on 95% confidence intervals or a p-value < 0.05 .

Results

After the exclusion of duplicates, our search identified 4,928 studies for abstract screening, of which 666 met the criteria for full-text review. We identified 148 studies that satisfied the inclusion criteria after full text review (Figure 1).

Figure 1. Flow diagram for study screening and selection

Seroprevalence

We identified 91 studies with seroprevalence data (13–103) from 29 countries, with serum collected between 1978 and 2017 (Figure 2).

Figure 2. Studies including HEV outbreak and serosurvey data over time, 1978-2017. Dots represent outbreak locations (centroid of lowest geographic unit of the outbreak identified) and colored polygons represent the number of serosurveys conducted in each country. Excludes 18 seroprevalence studies with unspecified study year.

Among studies that reported assay manufacturer (85%; 77/91), anti-HEV IgG antibodies were assessed using 18 different commercial assays as well as in-house assays (e.g. Walter Reed Army Institute of Research in-house assay). The most common assays used to assess seroprevalence were in-house assays (21%) (14,34,44,47,51,53,56,60,61,70,72,79,84,91,97,100), Wantai (18%; Wantai BioPharm, Beijing, China) (20–23,31,40,46,48,54,59,63,65,76,77), and Abbott (14%; (Abbott

Diagnostika, Germany) (15,18,28,32,43,80,82,83,87,93,94) with the Wantai assay becoming the most commonly used assay in studies conducted in the last 5 years of the review (2013-2017).

HEV seropositivity, in general, increased with age among all population groups except occupational groups exposed to animals (Figure 3).

Figure 3. Age seroprevalence curves by varying population types in 29 countries, 1978-2017. Excludes seroprevalence estimates with no specified age bounds and 1 study with unspecified location. Population types include general population, blood donors, patients attending a hospital or clinic for non-liver related, non-pregnancy related issues (hospital), pregnant women, occupational groups exposed to animals (occupational), outbreak residents, or other. Black line represents the best fit linear trend between age and seropositivity.

Age-specific seroprevalence estimates, excluding occupational groups and outbreak residents, increased by age with all assays used, except Abbott (Supplemental Figure 1).

Outbreaks

We identified 51 outbreak reports (30,50,78,82,85,93,104–107,107–148) describing 49 completed or on-going outbreaks occurring in 18 countries between 1988 and 2017. Among outbreaks with reported locations (48/49), outbreaks were identified in Africa (43%) and Asia (57%), with over half of outbreaks reported from 3 countries: India (35%) (30,106,107,109,110,114,117,121,125,128,136–138,141,145,147,148), Sudan (10%) (119,133,140,143,144), and Uganda (8%) (78,85,108,126,129). Reported outbreak durations ranged from 28 days (Yangon, Myanmar) (142) to 3.2 years (Karamoja region, Uganda) (126) (Median: 166 days; IQR: 91-303). At least one large-scale outbreak with over 5,000 suspected cases occurred in every decade since 1988, and outbreaks in the last 15 years (2004-2017) had a median of 1152 suspected cases reported (IQR: 252-2362). Among all outbreaks, 12% occurred in refugee camp/informal

settlements (N=6) (50,78,111,119,123,123), with 31% of all suspected cases (24,341/77,372 suspected cases) identified in our review occurring in these settings.

Confirmatory serologic testing (i.e., IgM) was conducted for 10% of all suspected cases reported in outbreaks (7,956/77,372), including 15 small outbreaks (<500 suspected cases) in which 100% of all suspected cases had confirmatory serologic testing (30,82,93,113,118,121,122,125,129,134,135,140,142–144). Among outbreaks where at least some cases were laboratory confirmed (N=47), 94% of confirmed case definitions included serologic confirmation of HEV IgM and 21% included HEV RNA. Overall, 43% of all suspected cases were identified in health facilities, 42% were identified within the community, 1% were identified in institutions (e.g. military training camps, prisons), and 13% were identified in unknown locations.

Among studies reporting data on deaths (34/49), the CFR ranged from 0-28% among suspected cases (mean: 2; SD: 6) and 0-28% among confirmed cases (mean: 3; SD: 7). Fewer outbreak reports had available data on deaths among pregnant women (20/48), and the CFR among pregnant women ranged from 0-33% among suspected cases (mean: 11; SD: 10) and 0-65% among confirmed cases (mean: 28; SD: 24) (50,78,82,104,106,108,112–114,117,119,120,123,124,126–129,140,146). The highest CFR (65%; 15 fatalities among 23 confirmed pregnant cases) was reported among pregnant women in an outbreak in Napak district, Uganda which had over 1,300 confirmed cases of HEV in the overall population in 2013-2014 (108).

Risk Factors

Data on risk factors for HEV infection (defined by IgM antibodies or RNA), disease, and death were identified in 36 studies (17,21,26,30,34,46,63,68,74,85,91,92,102,104,108–110,112,116,129,138,139,145–158)

from 13 countries between 1990 and 2017. One study only reported risk factors with an unknown hypothesized direction of effect and was excluded from further analysis (159).

We identified only 2 studies (112,154) that examined risk factors for death and decided not to further summarize these limited data. Risk factors were predominantly for

confirmed disease (65%; 182/279), confirmed infection (25%; 70/279), followed by

suspected disease (8%; 23/279), and a mixture of suspected/confirmed disease (1%;

4/279). Studies investigating risk factors occurred in Africa (41%) and Asia (59%), and

33% of all individual risk factor estimates came from studies conducted in Bangladesh

(112,139,151,158). Most risk factor estimates included 95% confidence intervals (97%;

270/279) and were not adjusted for other covariates (74%; 206/279). The most common

risk factors examined were those categorized as “other” (24%; 68/279) and water (16%;

46/279). 43% of risk factors categorized as “other” (29/68) were related to

demographics and socioeconomic status (e.g. rural residence, household size, etc.;

Supplementary Table 1). Risk factors related to water included household sources of

water for drinking, cooking, or bathing, and water treatment and storage methods. 46%

of all studies investigating risk factors (16/35) were from HEV outbreaks

(30,85,104,108–110,112,116,119,129,138,139,145–148).

.

Based on the direction of effect estimates, 67% of effect estimates for water suggested increased risk of HEV with increased exposure to unimproved water sources and 33% of estimates showed the opposite trend or no effect (effect size = 0) (Figure 4). Effect estimates for sanitation and hygiene were similarly heterogeneous: 83% of sanitation-related estimates suggested increased risk with exposure to unimproved sanitation, and 71% of hygiene-related effect estimates suggested increased risk due to poor hygiene practices (e.g., never washing hands after defecating, etc.). Among estimates reported with a measure of statistical significance (76/79), a higher proportion of estimates for sanitation were statistically significant (33%) compared to estimates for water (21%) or hygiene (29%).

Figure 4. Risk factors for HEV infection or disease in 13 countries, 1990-2017. Risk factors were divided *a priori* into those hypothesized to decrease (blue) or increase (red) the likelihood of HEV infection or disease based on existing literature and the reference group for each estimator (Supplemental Table 1). CI: 95% Confidence Interval.

Excludes 9 risk factor estimates not reported with corresponding 95% confidence intervals.

Increased risk of HEV infection/disease (effect size >1) was identified in a majority of effect estimates related to exposures to food and drink (82% of estimates), blood (81%), and animals (72%). Food and drink exposures (N=33), were predominantly assessed with questions related to consumption of meat (42%) and juices/sodas (24%). The majority of assessed exposures to blood (N=16) were related to blood transfusions (38%) and recent injections (25%). The majority of assessed exposures to animals (N=25) were related to the presence of animals (pets or varmints) in compounds/homes (32%), occupational exposures (24%), any contact with animals (16%), and livestock ownership (16%). Only 21% (7/33) of effect estimates related to food/drink exposures were statistically significant, while 38% (6/16) of estimates for blood exposures and 20% (5/25) of estimates for animal exposures were significant.

The directionality of effect estimates was consistent with the hypothesis that older age increases risk of HEV infection/disease in 52% of estimates for confirmed disease and 54% of estimates for confirmed infection, as would be expected by chance. Effect estimates related to age were statistically significant for 40% (10/25) of estimates for confirmed disease and 8% (1/12) of estimates for confirmed infection. 82% (9/11) of estimates that were statistically significant suggested increased risk for confirmed HEV disease/infection with older age.

In 72% of estimates (13/18) males had a higher risk of infection/disease than females.

Among estimates reported with a measure of statistical significance (17/18), 41% were statistically significant.

Discussion

Through a synthesis of published literature we highlight the persistent burden of hepatitis E genotypes 1 and 2 in LMICs and suggest that zoonotic and blood borne transmission may be contributing to this burden in addition to fecal-oral transmission.

Although studies on HEV burden have expanded geographically over time, existing data are insufficient to identify temporal or geographic trends in risk. Similar to other reviews, we note challenges in interpreting and comparing data from different studies due to variability in diagnostic assays used, definitions of suspected and confirmed cases of HEV (160–162), and lack of standardized age groups used in analysis. Unified guidance and best practices for measuring disease burden and risk factors are urgently needed to generate evidence needed for developing a global strategy for hepatitis E control.

Given that most cases of hepatitis E are mild or asymptomatic and the lack of routine testing for hepatitis E among acute jaundice cases in LMICs, our knowledge on HEV burden of disease is largely limited to special studies and outbreak reports (163). Gaps in burden of disease data identified by WHO's Strategic Advisory Group of Experts on Immunization (SAGE) in 2015 as barriers to widespread introduction of hepatitis E vaccine remain largely unaddressed (7). A lack of data on the incidence of disease in the general population prevents the necessary investments in hepatitis E surveillance infrastructure, which cyclically limits our ability to quantify disease burden and advocate

for expanded use of the existing vaccine. Notably, the SARS-CoV-2 pandemic provides an opportunity to break this cycle due to the increased number of representative population-based surveys that have been conducted (164). Leveraging remnant samples from these studies could provide a cost-effective way of greatly increasing our understanding of the global burden of hepatitis E (165).

Our findings emphasize how a reliance on data from outbreak reports can obscure potentially important HEV transmission pathways. Trends suggestive of increased risk for infection and disease due to exposures to animals and consumption of meat suggest that HEV genotypes 3 and 4 may be responsible for some of the hepatitis E burden. Our findings suggest that sporadic hepatitis cases in LMIC may also be due to blood borne transmission of HEV, which is most likely to be caused by the predominant circulating genotype within each population (151). However, our ability to draw conclusions about the role of zoonotic and blood-borne transmission is limited given that only 27% of studies with data on risk factors adjusted for potentially confounding variables such as socioeconomic status. Our ability to identify key risk factors is further limited by the fact that most ‘controls’ in case-control studies were recruited on the basis of not having hepatitis E disease with the assumption that they were still at-risk. Some of these controls were almost certainly previously exposed to HEV, which would lead to reduced power, and in some cases bias, in estimates of risk factors (166). A better understanding of the frequency of HEV infection due to transmission routes such as zoonotic transmission and blood-borne transmission in endemic countries may justify potentially life-saving interventions such as blood donor screening for HEV.

WHO has recommended the vaccine be considered as a strategy to prevent and mitigate outbreaks, particularly among high-risk groups such as pregnant women (7). The current vaccine's three dose schedule given across 6 months introduces logistical constraints to rapidly deploying vaccines in outbreaks (167). While reduced dose regimens may confer protection against HEV (6), the multi-year protracted outbreaks identified in our review suggest the potential for even a three dose regimen to substantially prevent morbidity and mortality among the world's most vulnerable populations. While we note that CFRs may be overestimated in studies relying on health facilities for case detection, the average case fatality risk among confirmed pregnant cases in outbreaks in this review was 9.3 times higher than confirmed cases in the general population. Field studies are urgently needed to evaluate the safety and effectiveness of the existing hepatitis E vaccine subpopulations such as refugees and pregnant women who are disproportionately affected by the burden of HEV.

This review has several limitations. We did not conduct any formal risk of bias assessments, and did not exclude any studies on the basis of sample size. Trends in risk factor data may have been under or overestimated due to the inclusion of low quality estimates. We underestimated the number of HEV outbreaks in LMIC due to limited publishing of outbreaks in peer-reviewed journals and our exclusion of less formal outbreak reports, such as the WHO Outbreaks and Emergencies bulletin. Outbreak reports were often based on research investigations of outbreak etiology rather than comprehensive assessments of outbreak size, leading to an underestimation of the burden of outbreaks. Age-specific seroprevalence curves stratified by population type were generated using data from diverse diagnostic assays

which have varying sensitivity and specificity, and therefore may not represent true age-specific patterns. Finally, our ability to draw conclusions from risk factor data is limited given our inclusion of unadjusted and adjusted estimators collected from varying population types. Nevertheless, we identify key trends in the force of infection of HEV and risk factors for transmission that warrant further investigation in future studies.

Addressing outstanding gaps in our understanding of the epidemiology of HEV in LMICs is critical to justify the funds needed for expanded use of the vaccine following pre-qualification. Standardized guidelines defining best practices for study design and exposure and outcome measurement in hepatitis E research are needed to identify key areas with elevated incidence of HEV infection where the vaccine may be a cost-effective tool to prevent avoidable morbidity and mortality. Guidelines are also needed to define a minimum set of risk factors for which data should be collected in all HEV outbreak investigations and risk factor studies, including: sociodemographic variables (e.g. SES, age, sex), WASH, and exposures to animals and blood. Broad control of hepatitis E with existing tools and strategies is possible, but requires a unified global strategy and the inclusion of hepatitis E in the agendas of researchers, public health authorities, and funders.

Funding statement

This work was supported by the Bill and Melinda Gates Foundation (INV-0166643; recipient AA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology*. 2012 Apr;55(4):988–97.
2. Aggarwal R. The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review [Internet]. Geneva, Switzerland: World Health Organization; 2010 Dec. Available from: www.who.int/vaccines-documents/
3. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. *The Lancet*. 2012 Jun 30;379(9835):2477–88.
4. Purcell RH, Emerson SU. Hepatitis E: An emerging awareness of an old disease. *Journal of Hepatology*. 2008 Mar 1;48(3):494–503.
5. Guthmann J-P, Klovstad H, Boccia D, Hamid N, Pinoges L, Nizou J-Y, et al. A Large Outbreak of Hepatitis E among a Displaced Population in Darfur, Sudan, 2004: The Role of Water Treatment Methods. *Clin Infect Dis*. 2006 Jun 15;42(12):1685–91.
6. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *Lancet*. 2010 Sep 11;376(9744):895–902.
7. World Health Organization. Hepatitis E vaccine: WHO position Paper. 2015 p. 185–200. (*Wkly Epidemiol Rec* 90:).
8. Cooper BS, White LJ, Siddiqui R. Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study. *PLoS Negl Trop Dis*. 2018;12(9):e0006807.
9. World Health Organization. Recommendations to assure the quality, safety and efficacy of recombinant hepatitis E vaccines [Internet]. 2018. Available from: https://www.who.int/biologicals/expert_committee/POST_ECBS_2018_Recommendations_HEP_E_vaccines.pdf?ua=1
10. World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2020 Jul 12]. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>
11. Kmush BL, Labrique AB, Dalton HR, Ahmed ZB, Ticehurst JR, Heaney CD, et al. Two Generations of “Gold Standards”: The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence. *Am J Trop Med Hyg*. 2015 Oct 7;93(4):714–7.
12. United Nations Children’s Fund (UNICEF), World Health Organization. Progress on household drinking water, sanitation and hygiene 2000-2017: Special focus on inequalities. New York; 2019.
13. Adjei A.A., Tettey Y., Aveyase J.T., Adu-Gyamfi C., Mingle J.A., Nartey E.T. Unexpected elevated alanine aminotransferase, aspartate aminotransferase levels and hepatitis e virus infection among persons who work with pigs in Accra, Ghana. *Virology Journal* [Internet]. 2010;7((Nartey E.T., etnartey@yahoo.com) Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, Accra, Ghana). Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L360086664>
14. Kmush BL., Labrique A., Li W., Klein SL., Schulze K., Shaikh S., et al. The Association of Cytokines and Micronutrients with Hepatitis E Virus Infection During Pregnancy and the Postpartum Period in Rural Bangladesh. *The American journal of tropical medicine and hygiene*. 2016;94(1):203–11.

15. Khuroo MS., Rustgi VK., Dawson GJ., Mushahwar IK., Yattoo GN., Kamili S., et al. Spectrum of hepatitis E virus infection in India. *Journal of medical virology*. 1994;43(3):281–6.
16. Vivek R., Chandy GM., Brown DW., Kang G. Seroprevalence of IgG antibodies to hepatitis E in urban and rural southern India. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2010;104(4):307–8.
17. Houcine N., Jacques R., Salma F., Anne-Gaëlle D., Amin S., Mohsen H., et al. Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2012;18(5):E119-21.
18. Aubry P., Niel L., Niyongabo T., Kerguelen S., Larouze B. Seroprevalence of hepatitis E virus in an adult urban population from Burundi. *The American journal of tropical medicine and hygiene*. 1997;57(3):272–3.
19. Jafri W., Yakoob J., Abid S., Awan S., Siddiqui S., Jafri F., et al. Seroprevalence of hepatitis E and *Helicobacter pylori* in a low socioeconomic area of a metropolitan city in a developing country. *British journal of biomedical science*. 2013;70(1):27–30.
20. Taha TE., Rusie LK., Labrique A., Nyirenda M., Soko D., Kamanga M., et al. Seroprevalence for Hepatitis E and Other Viral Hepatitis among Diverse Populations, Malawi. *Emerging infectious diseases*. 2015;21(7):1174–82.
21. Vernier L., Lenglet A., Hogema BM., Moussa AM., Ariti C., Vollmer S., et al. Seroprevalence and risk factors of recent infection with hepatitis E virus during an acute outbreak in an urban setting in Chad, 2017. *BMC infectious diseases*. 2018;18(1):287.
22. Abebe M., Ali I., Ayele S., Overbo J., Aseffa A., Mihret A. Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women in Addis Ababa, Ethiopia. *PloS one*. 2017;12(6):e0180078.
23. Niguse S., Hailekiros H., Buruh G., Dejene T., Berhe N., Asmelash T. Seroprevalence and risk factors of Hepatitis E virus infection among pregnant women attending antenatal care in health facilities of Tigray, Northern Ethiopia. *Journal of medical virology*. 2018;90(8):1364–9.
24. Hannachi N., Hidar S., Harrabi I., Mhalla S., Marzouk M., Ghzel H., et al. [Seroprevalence and risk factors of hepatitis E among pregnant women in central Tunisia]. *Pathologie-biologie*. 2011;59(5):e115-8.
25. Ekanem E., Ikobah J., Okpara H., Udo J. Seroprevalence and predictors of hepatitis E infection in Nigerian children. *Journal of infection in developing countries*. 2015;9(11):1220–5.
26. Furukawa NW., Teshale EH., Cosmas L., Ochieng M., Gikunju S., Fields BS., et al. Serologic evidence for hepatitis E virus infection among patients with undifferentiated acute febrile illness in Kibera, Kenya. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2016;77:106–8.
27. Jacobs C., Chiluba C., Phiri C., Lisulo MM., Chomba M., Hill PC., et al. Seroepidemiology of hepatitis E virus infection in an urban population in Zambia: strong association with HIV and environmental enteropathy. *The Journal of infectious diseases*. 2014;209(5):652–7.
28. Kamel MA., Troonen H., Kapprell HP., el-Ayady A., Miller FD. Seroepidemiology of hepatitis E virus in the Egyptian Nile Delta. *Journal of medical virology*. 1995;47(4):399–403.
29. Bawazir AA., Hart CA., Sallam TA., Parry CM., Beeching NJ., Cuevas LE. Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2010;104(12):801–5.
30. Khuroo MS., Khuroo MS. Seroepidemiology of a second epidemic of hepatitis E in a population that had recorded first epidemic 30 years before and has been under surveillance since then. *Hepatology international*. 2010;4(2):494–9.
31. Bansal M., Kaur S., Deka D., Singh R., Gill JPS. Seroepidemiology and molecular characterization of hepatitis E virus infection in swine and occupationally exposed workers in Punjab, India. *Zoonoses and public health*. 2017;64(8):662–72.

32. Benjelloun S., Bahbouhi B., Bouchrit N., Cherkaoui L., Hda N., Mahjour J., et al. Seroepidemiological study of an acute hepatitis E outbreak in Morocco. *Research in virology*. 148(4):279–87.
33. Obiri-Yeboah D., Asante Awuku Y., Adu J., Pappoe F., Obboh E., Nsiah P., et al. Sero-prevalence and risk factors for hepatitis E virus infection among pregnant women in the Cape Coast Metropolis, Ghana. *PloS one*. 2018;13(1):e0191685.
34. Mathur P., Arora NK., Panda SK., Kapoor SK., Jailkhani BL., Irshad M. Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. *Indian pediatrics*. 2001;38(5):461–75.
35. Das K., Agarwal A., Andrew R., Frösner GG., Kar P. Role of hepatitis E and other hepatotropic virus in aetiology of sporadic acute viral hepatitis: a hospital based study from urban Delhi. *European journal of epidemiology*. 2000;16(10):937–40.
36. Abdel Rahman MM., Massoud AM., Kamel MA., Sabry AH., Ahmed GN. Risk of hepatitis “E” virus infection among some schistosomiasis patients in Egypt. *Journal of the Egyptian Society of Parasitology*. 1995;25(1):115–23.
37. Carmoi T., Safiullah S., Nicand E. Risk of enterically transmitted hepatitis A, hepatitis E, and Plasmodium falciparum malaria in Afghanistan. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2009;48(12):1800.
38. Arankalle VA., Chobe LP. Retrospective analysis of blood transfusion recipients: evidence for post-transfusion hepatitis E. *Vox sanguinis*. 2000;79(2):72–4.
39. Clayson ET., Shrestha MP., Vaughn DW., Snitbhan R., Shrestha KB., Longer CF., et al. Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal. *The Journal of infectious diseases*. 1997;176(3):763–6.
40. Katiyar H., Goel A., Sonker A., Yadav V., Sapun S., Chaudhary R., et al. Prevalence of hepatitis E virus viremia and antibodies among healthy blood donors in India. *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*. 2018;37(4):342–6.
41. Chandra NS., Ojha D., Chatterjee S., Chattopadhyay D. Prevalence of hepatitis E virus infection in West Bengal, India: a hospital-based study. *Journal of medical microbiology*. 2014;63(Pt 7):975–80.
42. Utsumi T., Hayashi Y., Lusida MI., Amin M., Soetjipto ., Hendra A., et al. Prevalence of hepatitis E virus among swine and humans in two different ethnic communities in Indonesia. *Archives of virology*. 2011;156(4):689–93.
43. Fix AD., Abdel-Hamid M., Purcell RH., Shehata MH., Abdel-Aziz F., Mikhail N., et al. Prevalence of antibodies to hepatitis E in two rural Egyptian communities. *The American journal of tropical medicine and hygiene*. 2000;62(4):519–23.
44. Mohanavalli B., Dhevahi E., Menon T., Malathi S., Thyagarajan SP. Prevalence of antibodies to hepatitis A and hepatitis E virus in urban school children in Chennai. *Indian pediatrics*. 2003;40(4):328–31.
45. Agarwal SK., Irshad M., Dash SC. Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India. *Nephron*. 1999;81(4):448.
46. Shrestha A., Adhikari A., Bhattarai M., Rauniyar R., Debes JD., Boonstra A., et al. Prevalence and risk of hepatitis E virus infection in the HIV population of Nepal. *Virology journal*. 2017;14(1):228.
47. Labrique AB., Zaman K., Hossain Z., Saha P., Yunus M., Hossain A., et al. Population seroprevalence of hepatitis E virus antibodies in rural Bangladesh. *The American journal of tropical medicine and hygiene*. 2009;81(5):875–81.
48. Nouhin J., Barenes H., Madec Y., Prak S., Hou SV., Kerleguer A., et al. Low frequency of acute hepatitis E virus (HEV) infections but high past HEV exposure in subjects from Cambodia with mild liver enzyme elevations, unexplained fever or immunodeficiency due to HIV-1 infection. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2015;71:22–7.

49. Naik A., Gupta N., Goel D., Ippagunta SK., Sharma RK., Aggarwal R. Lack of evidence of hepatitis E virus infection among renal transplant recipients in a disease-endemic area. *Journal of viral hepatitis*. 2013;20(4):e138-40.
50. Thomson K., Luis Dvorzak J., Lagu J., Laku R., Dineen B., Schilperoord M., et al. Investigation of hepatitis E outbreak among refugees - Upper Nile, South Sudan, 2012-2013. *Morbidity and Mortality Weekly Report*. 2013;62(29):581-6.
51. Vaidya SR., Tilekar BN., Walimbe AM., Arankalle VA. Increased risk of hepatitis E in sewage workers from India. *Journal of occupational and environmental medicine*. 2003;45(11):1167-70.
52. Temmam S., Besnard L., Andriamandimby SF., Foray C., Rasamoelina-Andriamanivo H., Héraud JM., et al. High prevalence of hepatitis E in humans and pigs and evidence of genotype-3 virus in swine, Madagascar. *The American journal of tropical medicine and hygiene*. 2013;88(2):329-38.
53. Stoszek SK., Abdel-Hamid M., Saleh DA., El Kafrawy S., Narooz S., Hawash Y., et al. High prevalence of hepatitis E antibodies in pregnant Egyptian women. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006;100(2):95-101.
54. Azman A.S., Bouhenia M., Iyer A.S., Rumunu J., Deng L.L., Wamala J.F., et al. High hepatitis e seroprevalence among displaced persons in south sudan: Evidence of undetected transmission and implications for vaccination. *American Journal of Tropical Medicine and Hygiene*. 2016;95(5):593.
55. Khounvisith V., Tritz S., Khenkha L., Phoutana V., Keosengthong A., Pommasichan S., et al. High circulation of Hepatitis E virus in pigs and professionals exposed to pigs in Laos. *Zoonoses and public health*. 2018;
56. Skidmore SJ., Yarbough PO., Gabor KA., Reyes GR. Hepatitis E virus: the cause of a waterbourne hepatitis outbreak. *Journal of medical virology*. 1992;37(1):58-60.
57. Arankalle VA, Chobe LP. Hepatitis E virus: can it be transmitted parenterally? *J Viral Hepat*. 1999 Mar;6(2):161-4.
58. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. *Hepatology*. 2002 Aug;36(2):474-8.
59. Izopet J., Labrique AB., Basnyat B., Dalton HR., Kmush B., Heaney CD., et al. Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2015;70:39-42.
60. Martinson FE., Marfo VY., Degraaf J. Hepatitis E virus seroprevalence in children living in rural Ghana. *West African journal of medicine*. 18(2):76-9.
61. Boon D., Redd AD., Laeyendecker O., Engle RE., Nguyen H., Ocamo P., et al. Hepatitis E Virus Seroprevalence and Correlates of Anti-HEV IgG Antibodies in the Rakai District, Uganda. *The Journal of infectious diseases*. 2018;217(5):785-9.
62. Ben-Ayed Y., Hannachi H., Ben-Alaya-Bouafif N., Gouider E., Triki H., Bahri O. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). *Journal of medical virology*. 2015;87(3):441-5.
63. Shrestha AC., Flower RL., Seed CR., Rajkarnikar M., Shrestha SK., Thapa U., et al. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal. *BMC infectious diseases*. 2016;16(1):707.
64. Caron M., Kazanji M. Hepatitis E virus is highly prevalent among pregnant women in Gabon, central Africa, with different patterns between rural and urban areas. *Virology journal*. 2008;5:158.
65. Vivek R., Kang G. Hepatitis E virus infections in swine and swine handlers in Vellore, Southern India. *The American journal of tropical medicine and hygiene*. 2011;84(4):647-9.
66. Feldt T., Sarfo FS., Zoufaly A., Phillips RO., Burchard G., van Lunzen J., et al. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2013;58(1):18-23.

67. Patel RC., Kamili S., Teshale E. Hepatitis E virus infections in children age 0-15, Uganda outbreak, 2007. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2015;73:112–4.
68. Khuroo MS., Kamili S., Yattoo GN. Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. *Journal of gastroenterology and hepatology*. 2004;19(7):778–84.
69. Adjei AA., Tettey Y., Aviyase JT., Adu-Gyamfi C., Obed S., Mingle JA., et al. Hepatitis E virus infection is highly prevalent among pregnant women in Accra, Ghana. *Virology journal*. 2009;6:108.
70. Myint KS., Duripunt P., Mammen MP., Sirisopana N., Rodkvamtook W., Gibbons RV. Hepatitis E virus infection in Thai troops deployed with U.N. peacekeeping forces. *Military medicine*. 2007;172(11):1217–9.
71. Meldal BH., Sarkodie F., Owusu-Ofori S., Allain JP. Hepatitis E virus infection in Ghanaian blood donors - the importance of immunoassay selection and confirmation. *Vox sanguinis*. 2013;104(1):30–6.
72. Sheikh A., Sugitani M., Kinukawa N., Moriyama M., Arakawa Y., Komiyama K., et al. Hepatitis e virus infection in fulminant hepatitis patients and an apparently healthy population in Bangladesh. *The American journal of tropical medicine and hygiene*. 2002;66(6):721–4.
73. Shimakawa Y., Njai HF., Takahashi K., Berg L., Ndow G., Jeng-Barry A., et al. Hepatitis E virus infection and acute-on-chronic liver failure in West Africa: a case-control study from The Gambia. *Alimentary pharmacology & therapeutics*. 2016;43(3):375–84.
74. Adjei AA., Aviyase JT., Tettey Y., Adu-Gyamfi C., Mingle JA., Ayeh-Kumi PF., et al. Hepatitis E virus infection among pig handlers in Accra, Ghana. *East African medical journal*. 2009;86(8):359–63.
75. Mohamed S.Y., Emam E.A., Omar A.A., El-Aziz Gaber O.A. Hepatitis E virus IgG in serum of pregnant women. *Journal of Gastroenterology and Hepatology Research*. 2017;6(5):2435–40.
76. Harritshøj LH., Theilgaard ZP., Mannheimer E., Midgley SE., Chiduo M., Ullum H., et al. Hepatitis E virus epidemiology among HIV-infected women in an urban area in Tanzania. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2018;73:7–9.
77. Nouhin J., Prak S., Madec Y., Barennes H., Weissel R., Hok K., et al. Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). *Transfusion*. 2016;56(10):2597–601.
78. Teshale EH., Howard CM., Grytdal SP., Handzel TR., Barry V., Kamili S., et al. Hepatitis E epidemic, Uganda. *Emerging infectious diseases*. 2010;16(1):126–9.
79. Stoszek SK., Engle RE., Abdel-Hamid M., Mikhail N., Abdel-Aziz F., Medhat A., et al. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006;100(2):89–94.
80. Amer AF., Zaki SA., Nagati AM., Darwish MA. Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance. *The Journal of the Egyptian Public Health Association*. 1996;71(3–4):273–84.
81. Gupta BP., Lama TK., Adhikari A., Shrestha A., Rauniyar R., Sapkota B., et al. First report of hepatitis E virus viremia in healthy blood donors from Nepal. *Virusdisease*. 2016;27(3):324–6.
82. Sedyaningsih-Mamahit ER., Larasati RP., Laras K., Sidemen A., Sukri N., Sabaruddin N., et al. First documented outbreak of hepatitis E virus transmission in Java, Indonesia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 96(4):398–404.
83. Qureshi H., Shahid A., Mujeeb SA. Exposer rate of hepatitis E (IgG) in a selected population of children and adults in Karachi. *JPMA The Journal of the Pakistan Medical Association*. 2000;50(10):352–4.

84. El-Esnawy NA. Examination for hepatitis E virus in wastewater treatment plants and workers by nested RT-PCR and ELISA. *The Journal of the Egyptian Public Health Association*. 2000;75(1–2):219–31.
85. Teshale EH., Grytdal SP., Howard C., Barry V., Kamili S., Drobeniuc J., et al. Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(7):1006–10.
86. Tritz SE., Khounvisith V., Pommasichan S., Ninnasopha K., Keosengthong A., Phoutana V., et al. Evidence of increased Hepatitis E virus exposure in Lao villagers with contact to ruminants. *Zoonoses and public health*. 2018;
87. Aggarwal R., Shahi H., Naik S., Yachha SK., Naik SR. Evidence in favour of high infection rate with hepatitis E virus among young children in India. *Journal of hepatology*. 1997;26(6):1425–6.
88. Amarapurkar D., Agal S., Baijal R., Gupte P., Patel N., Kamani P., et al. Epidemiology of hepatitis E virus infection in Western India. *Hepatitis Monthly*. 2008;8(4):258–62.
89. De Paschale M., Ceriani C., Romanò L., Cerulli T., Cagnin D., Cavallari S., et al. Epidemiology of hepatitis E virus infection during pregnancy in Benin. *Tropical medicine & international health : TM & IH*. 2016;21(1):108–13.
90. Al Mahtab M., Rahman S., Jahan M., Khondoker F.A., Akbar S.M.F. Epidemiology of hepatitis E virus in an urban community in Dhaka city. *Hepatology International*. 2013;7((Akbar S.M.F.) Medical Sciences, Toshiba General Hospital, Tokyo, Japan):S727.
91. Labrique AB., Zaman K., Hossain Z., Saha P., Yunus M., Hossain A., et al. Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh. *American journal of epidemiology*. 2010;172(8):952–61.
92. Junaid SA., Agina SE., Abubakar KA. Epidemiology and associated risk factors of hepatitis e virus infection in plateau state, Nigeria. *Virology : research and treatment*. 2014;5:15–26.
93. Bryan J.P., Iqbal M., Tsarev S., Malik I.A., Duncan J.F., Ahmed A., et al. Epidemic of hepatitis E in a military unit in Abbottabad, Pakistan. *American Journal of Tropical Medicine and Hygiene*. 2002;67(6):662–8.
94. Corwin A., Putri MP., Winarno J., Lubis I., Suparmanto S., Sumardiati A., et al. Epidemic and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. *The American journal of tropical medicine and hygiene*. 1997;57(1):62–5.
95. Lorenzo A.A., De Guzman T.S., Su G.L.S. Detection of IgM and IgG antibodies against hepatitis E virus in donated blood bags from a national voluntary blood bank in Metro Manila, Philippines. *Asian Pacific Journal of Tropical Disease*. 2015;5(8):604–5.
96. El Sayed Zaki M., El Aal AA., Badawy A., El-Deeb DR., El-Kheir NY. Clinicolaboratory study of mother-to-neonate transmission of hepatitis E virus in Egypt. *American journal of clinical pathology*. 2013;140(5):721–6.
97. Murhekar MV., Sehgal SC., Murhekar KM., Padbhidri SP., Chitambar SD., Arankalle VA. Changing scenario of hepatitis A virus and hepatitis E virus exposure among the primitive tribes of Andaman and Nicobar Islands, India over the 10-year period 1989-99. *Journal of viral hepatitis*. 2002;9(4):315–21.
98. Arankalle VA., Chadha MS., Chitambar SD., Walimbe AM., Chobe LP., Gandhe SS. Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982-98). *Journal of viral hepatitis*. 2001;8(4):293–303.
99. Daniel HD., Warier A., Abraham P., Sridharan G. Age-wise exposure rates to hepatitis e virus in a southern Indian patient population without liver disease. *The American journal of tropical medicine and hygiene*. 2004;71(5):675–8.
100. Hyams KC., Purdy MA., Kaur M., McCarthy MC., Hussain MA., el-Tigani A., et al. Acute sporadic hepatitis E in Sudanese children: analysis based on a new western blot assay. *The Journal of infectious diseases*. 1992;165(6):1001–5.

101. Somani SK., Aggarwal R., Naik SR., Srivastava S., Naik S. A serological study of intrafamilial spread from patients with sporadic hepatitis E virus infection. *Journal of viral hepatitis*. 2003;10(6):446–9.
102. Guthmann JP., Klovstad H., Boccia D., Hamid N., Pinoges L., Nizou JY., et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2006;42(12):1685–91.
103. Arankalle VA, Chadha MS, Mehendale SM, Tungatkar SP. Epidemic hepatitis E: serological evidence for lack of intrafamilial spread. *Indian J Gastroenterol*. 2000 Mar;19(1):24–8.
104. Rab MA., Bile MK., Mubarik MM., Asghar H., Sami Z., Siddiqi S., et al. Water-borne hepatitis E virus epidemic in Islamabad, Pakistan: a common source outbreak traced to the malfunction of a modern water treatment plant. *The American journal of tropical medicine and hygiene*. 1997;57(2):151–7.
105. Sazzad HM., Labrique AB., Teo CG., Luby SP., Gurley ES. Surveillance at Private Laboratories Identifies Small Outbreaks of Hepatitis E in Urban Bangladesh. *The American journal of tropical medicine and hygiene*. 2017;96(2):395–9.
106. Ganju SA, Gautam N, Walia S, Kanga A. Seroepidemiology of a recent outbreak of Hepatitis E in urban Shimla, Himachal Pradesh, India. *Journal of Communicable Diseases*. 2017;49(2):17–22.
107. Rai RR., Nijhawan S., Mathur A., Sharma MP., Udawat HP., Singh N. Seroepidemiology and role of polymerase chain reaction to detect viremia in an epidemic of hepatitis E in Western India. *Tropical gastroenterology : official journal of the Digestive Diseases Foundation*. 29(4):202–6.
108. Amany G., Kizito S., Nabukenya I., Kalyango J., Atuheire C., Nansumba H., et al. Risk factors, person, place and time characteristics associated with Hepatitis E Virus outbreak in Napak District, Uganda. *BMC infectious diseases*. 2017;17(1):451.
109. Sailaja B., Murhekar MV., Hutin YJ., Kuruva S., Murthy SP., Reddy KS., et al. Outbreak of waterborne hepatitis E in Hyderabad, India, 2005. *Epidemiology and infection*. 2009;137(2):234–40.
110. Banerjee A., Sahni AK., Rajiva ., Nagendra A., Saiprasad GS. Outbreak of Viral Hepatitis E in a Regimental Training Centre. *Medical journal, Armed Forces India*. 2005;61(4):326–9.
111. Lagare A., Ibrahim A., Ousmane S., Issaka B., Zaneidou M., Kadadé G., et al. Outbreak of Hepatitis E Virus Infection in Displaced Persons Camps in Diffa Region, Niger, 2017. *The American journal of tropical medicine and hygiene*. 2018;99(4):1055–7.
112. Gurley ES., Hossain MJ., Paul RC., Sazzad HM., Islam MS., Parveen S., et al. Outbreak of hepatitis E in urban Bangladesh resulting in maternal and perinatal mortality. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;59(5):658–65.
113. Coursaget P., Buisson Y., Enogat N., Bercion R., Baudet JM., Delmaire P., et al. Outbreak of enterically-transmitted hepatitis due to hepatitis A and hepatitis E viruses. *Journal of hepatology*. 1998;28(5):745–50.
114. Sarguna P., Rao A., Sudha Ramana KN. Outbreak of acute viral hepatitis due to hepatitis E virus in Hyderabad. *Indian journal of medical microbiology*. 2007;25(4):378–82.
115. Tsega E., Krawczynski K., Hansson BG., Nordenfelt E., Negusse Y., Alemu W., et al. Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. *Journal of medical virology*. 1991;34(4):232–6.
116. Siddiqui AR., Jooma RA., Smego RA. Nosocomial outbreak of hepatitis E infection in Pakistan with possible parenteral transmission. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2005;40(6):908–9.

117. Vivek R., Nihal L., Illiyaraja J., Reddy PK., Sarkar R., Eapen CE., et al. Investigation of an epidemic of Hepatitis E in Nellore in south India. *Tropical medicine & international health : TM & IH*. 2010;15(11):1333–9.
118. Bouscaillou J., Komas N., Tricou V., Nakouné E., Sélékon B., Fontanet A., et al. Imported hepatitis e virus, central african republic, 2011. *Emerging infectious diseases*. 2013;19(2):335–7.
119. Boccia D., Guthmann JP., Klovstad H., Hamid N., Tatay M., Ciglenecki I., et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2006;42(12):1679–84.
120. Escribà JM., Nakoune E., Recio C., Massamba PM., Matsika-Claquin MD., Goumba C., et al. Hepatitis E, Central African Republic. *Emerging infectious diseases*. 2008;14(4):681–3.
121. Kaur M., Sidhu SK., Singh K., Devi P., Kaur M., Singh NJ. Hepatitis E virus: A leading cause of waterborne viral hepatitis in Northwest Districts of Punjab, India. *Journal of laboratory physicians*. 9(2):121–4.
122. Jennings GB., Lubis I., Listiyaningsih E., Burans JP., Hyams KC. Hepatitis E virus in Indonesia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 88(1):57.
123. Ahmed JA., Moturi E., Spiegel P., Schilperoord M., Burton W., Kassim NH., et al. Hepatitis E outbreak, Dadaab refugee camp, Kenya, 2012. *Emerging infectious diseases*. 2013;19(6):1010–2.
124. Browne LB, Menkir Z, Kahi V, Maina G, Asnakew S, Tubman M, et al. Hepatitis e outbreak among refugees from south sudan — Gambella, Ethiopia, april 2014– january 2015. *Morbidity and Mortality Weekly Report*. 2015;64(19):537.
125. Arora NK., Panda SK., Nanda SK., Ansari IH., Joshi S., Dixit R., et al. Hepatitis E infection in children: study of an outbreak. *Journal of gastroenterology and hepatology*. 1999;14(6):572–7.
126. Cummings MJ, Wamala JF, Komakech I, Lukwago L, Malimbo M, Omeke ME, et al. Hepatitis E in Karamoja, Uganda, 2009–2012: epidemiology and challenges to control in a setting of semi-nomadic pastoralism. *Trans R Soc Trop Med Hyg*. 2014 Oct 1;108(10):648–55.
127. Shrestha A., Lama TK., Karki S., Sigdel DR., Rai U., Rauniyar SK., et al. Hepatitis E epidemic, Biratnagar, Nepal, 2014. *Emerging infectious diseases*. 2015;21(4):711–3.
128. Bali S., Kar SS., Kumar S., Ratho RK., Dhiman RK., Kumar R. Hepatitis E epidemic with bimodal peak in a town of north India. *Indian journal of public health*. 52(4):189–93, 199.
129. Gerbi GB., Williams R., Bakamutumaho B., Liu S., Downing R., Drobeniuc J., et al. Hepatitis E as a cause of acute jaundice syndrome in northern Uganda, 2010–2012. *The American journal of tropical medicine and hygiene*. 2015;92(2):411–4.
130. Maurice D., Abassora M., Marcelin N.M., Richard N. First documented outbreak of Hepatitis e in Northern Cameroon. *Annals of Tropical Medicine and Public Health*. 2013;6(6):682–3.
131. Harun-Or-Rashid M., Akbar SM., Takahashi K., Al-Mahtab M., Khan MS., Alim MA., et al. Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh. *Journal of medical virology*. 2013;85(8):1369–76.
132. Bile K., Isse A., Mohamud O., Allebeck P., Nilsson L., Norder H., et al. Contrasting roles of rivers and wells as sources of drinking water on attack and fatality rates in a hepatitis E epidemic in Somalia. *The American journal of tropical medicine and hygiene*. 1994;51(4):466–74.
133. Ahmed SS., Soghaier MA., Mohammed S., Khogali HS., Osman MM., Abdalla AM. Concomitant outbreaks of yellow fever and hepatitis E virus in Darfur States, Sudan, 2012. *Journal of infection in developing countries*. 2016;10(1):24–9.
134. Goumba Al., Konamna X., Komas NP. Clinical and epidemiological aspects of a hepatitis E outbreak in Bangui, Central African Republic. *BMC infectious diseases*. 2011;11:93.

135. Clayson ET., Vaughn DW., Innis BL., Shrestha MP., Pandey R., Malla DB. Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. *Journal of medical virology*. 1998;54(3):178–82.
136. Singh J., Aggarwal NR., Bhattacharjee J., Prakash C., Bora D., Jain DC., et al. An outbreak of viral hepatitis E: role of community practices. *The Journal of communicable diseases*. 1995;27(2):92–6.
137. Dwibedi B., Sabat J., Ho L.M., Pati S.S., Panda S., Kar S.K. An outbreak of hepatitis E virus infection caused by genotype 1 in an urban setting in eastern India: a probe into risk factors for transmission. *VirusDisease [Internet]*. 2018;((Kar S.K.) Life Science Research, IMS&SUM Hospital, SOA University, Bhubaneswar, India). Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L623986157>
138. Martolia HC., Hutin Y., Ramachandran V., Manickam P., Murhekar M., Gupte M. An outbreak of hepatitis E tracked to a spring in the foothills of the Himalayas, India, 2005. *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*. 28(3):99–101.
139. Haque F., Banu SS., Ara K., Chowdhury IA., Chowdhury SA., Kamili S., et al. An outbreak of hepatitis E in an urban area of Bangladesh. *Journal of viral hepatitis*. 2015;22(11):948–56.
140. Rayis DA., Jumaa AM., Gasim GI., Karsany MS., Adam I. An outbreak of hepatitis E and high maternal mortality at Port Sudan, Eastern Sudan. *Pathogens and global health*. 2013;107(2):66–8.
141. Neogi DK., Bhattacharya N., De PN., Chakravarti T., Hati AK., Prakash C., et al. An institutional outbreak of hepatitis E--reported first time from Calcutta city. *The Journal of communicable diseases*. 1995;27(4):229–33.
142. Uchida T., Aye TT., Ma X., Iida F., Shikata T., Ichikawa M., et al. An epidemic outbreak of hepatitis E in Yangon of Myanmar: antibody assay and animal transmission of the virus. *Acta pathologica japonica*. 1993;43(3):94–8.
143. McCarthy MC., He J., Hyams KC., el-Tigani A., Khalid IO., Carl M. Acute hepatitis E infection during the 1988 floods in Khartoum, Sudan. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 88(2):177.
144. Elduma AH., Zein MM., Karlsson M., Elkhidir IM., Norder H. A Single Lineage of Hepatitis E Virus Causes Both Outbreaks and Sporadic Hepatitis in Sudan. *Viruses*. 2016;8(10).
145. Naik SR., Aggarwal R., Salunke PN., Mehrotra NN. A large waterborne viral hepatitis E epidemic in Kanpur, India. *Bulletin of the World Health Organization*. 1992;70(5):597–604.
146. Spina A., Lenglet A., Beversluis D., de Jong M., Vernier L., Spencer C., et al. A large outbreak of Hepatitis E virus genotype 1 infection in an urban setting in Chad likely linked to household level transmission factors, 2016-2017. *PloS one*. 2017;12(11):e0188240.
147. Swain SK., Baral P., Hutin YJ., Rao TV., Murhekar M., Gupte MD. A hepatitis E outbreak caused by a temporary interruption in a municipal water treatment system, Baripada, Orissa, India, 2004. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2010;104(1):66–9.
148. Aggarwal R., Kumar R., Pal R., Naik S., Semwal SN., Naik SR. Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*. 21(1):14–8.
149. Gomatos PJ., Monier MK., Arthur RR., Rodier GR., el-Zimaity D., Hassan NF., et al. Sporadic acute hepatitis caused by hepatitis E virus in Egyptian adults. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 1996;23(1):195–6.
150. Ukuli AQ., Mugimba KK. Seroprevalence of hepatitis E in swine abattoir workers. *African health sciences*. 2017;17(4):1022–8.
151. Sazzad HMS., Luby SP., Labrique AB., Kamili S., Hayden TM., Kamili NA., et al. Risk Factors Associated with Blood Exposure for Sporadic Hepatitis E in Dhaka, Bangladesh. *The American journal of tropical medicine and hygiene*. 2017;97(5):1437–44.

152. Eldin SS., Seddik I., Daef EA., Shata MT., Raafat M., Abdel Baky L., et al. Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in Assiut, Egypt. *The Egyptian journal of immunology*. 2010;17(1):73–86.
153. Howard CM., Handzel T., Hill VR., Grytdal SP., Blanton C., Kamili S., et al. Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: results from a case-control study and environmental analysis. *The American journal of tropical medicine and hygiene*. 2010;83(5):1170–3.
154. Bose PD., Das BC., Kumar A., Gondal R., Kumar D., Kar P. High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome. *Journal of hepatology*. 2011;54(6):1107–13.
155. Hoan NX., Tong HV., Hecht N., Sy BT., Marcinek P., Meyer CG., et al. Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients. *EBioMedicine*. 2015;2(12):2080–6.
156. Chau TN., Lai ST., Tse C., Ng TK., Leung VK., Lim W., et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. *The American journal of gastroenterology*. 2006;101(2):292–6.
157. Pathak R., Barde PV. Detection of Genotype 1a and 1f of Hepatitis E Virus in Patients Treated at Tertiary Care Hospitals in Central India. *Intervirolgy*. 2017;60(5):201–6.
158. Labrique AB., Zaman K., Hossain Z., Saha P., Yunus M., Hossain A., et al. An exploratory case control study of risk factors for hepatitis E in rural Bangladesh. *PloS one*. 2013;8(5):e61351.
159. Shata MT., Daef EA., Zaki ME., Abdelwahab SF., Marzuuk NM., Sobhy M., et al. Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2012;106(10):613–8.
160. Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. *Liver International*. 2020;40(7):1516–28.
161. The global burden of hepatitis E outbreaks: a systematic review - Hakim - 2017 - *Liver International* - Wiley Online Library [Internet]. [cited 2020 Jul 11]. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13237>
162. Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. *BMC Infect Dis*. 2014 Dec;14(1):308.
163. Azman AS, Ciglenecki I, Wamala JF, Lynch J, Aggarwal R, Rahman M, et al. Hepatitis E should be considered a neglected tropical disease. *PLoS Negl Trop Dis* [Internet]. 2019 Jul 25 [cited 2020 Jul 11];13(7). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657817/>
164. Chen X, Chen Z, Azman AS, Deng X, Chen X, Lu W, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *medRxiv* [Internet]. 2020 Oct 29 [cited 2020 Nov 18]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491537/>
165. Mina MJ, Metcalf CJE, McDermott AB, Douek DC, Farrar J, Grenfell BT. A Global Immunological Observatory to meet a time of pandemics. *Rosen CJ, Thakarak K, White M, editors. eLife*. 2020 Jun 8;9:e58989.
166. Chyou P-H. Patterns of bias due to differential misclassification by case-control status in a case-control study. *Eur J Epidemiol*. 2007;22(1):7–17.
167. Azman AS, Bouhenia M, Iyer AS, Rumunu J, Laku RL, Wamala JF, et al. High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan. *Am J Trop Med Hyg*. 2017 Jun;96(6):1296–301.